The biotech company, based in Princeton, New Jersey, focuses on creating novel therapeutics and supportive care products for cancer patients. Their products include a topical ointment for the treatment of hand-foot syndrome and a nucleoside analog inhibition of AKT, a key component in cancer cell growth and resistance to chemotherapy and radiotherapy. Founded in 2008, Cahaba Pharmaceuticals identifies and acquires rights to promising drug candidates to address medical needs in the oncology segment, providing healthcare institutions with new medicines to improve the quality of life for cancer patients.